Nyrada Inc
ASX:NYR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nyrada Inc
Operating Expenses
Nyrada Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nyrada Inc
ASX:NYR
|
Operating Expenses
-AU$8.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Operating Expenses
-AU$27.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Expenses
-AU$324.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Expenses
-AU$42.6m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-9%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Operating Expenses
-AU$69.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Operating Expenses
-AU$43m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
Nyrada Inc
Glance View
Nyrada, Inc. operates as a pre-clinical stage, drug development company. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. The company is also developing new therapies.
See Also
What is Nyrada Inc's Operating Expenses?
Operating Expenses
-8.1m
AUD
Based on the financial report for Dec 31, 2025, Nyrada Inc's Operating Expenses amounts to -8.1m AUD.
What is Nyrada Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-2%
Over the last year, the Operating Expenses growth was -38%. The average annual Operating Expenses growth rates for Nyrada Inc have been -10% over the past three years , -2% over the past five years .
